Literature DB >> 15361497

Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

A Bassi1, S Dodd, P Williamson, K Bodger.   

Abstract

BACKGROUND AND AIMS: The potentially high costs of care associated with inflammatory bowel disease (IBD) are recognised but we have little knowledge of the scale, profile, or determinants of these costs in the UK. This study aimed to describe costs of illness for a group of IBD patients and determine factors associated with increased healthcare costs.
SETTING: A university hospital serving a target population of approximately 330 000. PATIENTS AND METHODS: A six month cohort of IBD patients receiving any form of secondary care was identified, comprising 307 cases of ulcerative (or indeterminate) colitis and 172 cases of Crohn's disease. Demographic and clinical data were abstracted from clinical records and individual resource use was itemised for all attributable costs (including extraintestinal manifestations). Item costs were derived from national and local sources. Cost data were expressed as mean six month costs per patient (with 95% confidence interval (CI)) obtained using non-parametric bootstrapping. Determinants of cost were analysed using generalised linear regression modelling. A postal survey of patients was undertaken to examine indirect costs, out of pocket expenses, and primary care visits.
RESULTS: Inpatient services (medical and/or surgical) were required by 67 patients (14%) but accounted for 49% of total secondary care costs. Drug costs accounted for less than a quarter of total costs. Individual patient costs ranged from 73 to 33,254 UK pounds per six months. Mean (95% CI) six month costs per patient were 1256 UK pounds ( 988 pounds, 1721 pounds) for colitis and 1652 UK pounds (1221 pounds, 2239 pounds) for Crohn's disease. Hospitalisation, disease severity grade, and disease extent correlated positively with cost of illness but costs were independent of age or sex. Compared with quiescent cases of IBD, disease relapse was associated with a 2-3-fold increase in costs for non-hospitalised cases and a 20-fold increase in costs for hospitalised cases. Survey data suggested average six month costs were < 30 UK pounds per patient for primary care visits (both diseases) and median loss of earnings were 239 UK pounds for colitis and 299 UK pounds for Crohn's disease.
CONCLUSIONS: This study represents the first detailed characterisation of the scale and determinants of costs of illness for IBD in a British hospital. Hospitalisation affected a minority of sufferers but accounted for half of the total direct costs falling on the healthcare system.

Entities:  

Mesh:

Year:  2004        PMID: 15361497      PMCID: PMC1774248          DOI: 10.1136/gut.2004.041616

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  The impact of inflammatory bowel disease on labor force participation: results of a population sampled case-control study.

Authors:  Annelies Boonen; Pieter C Dagnelie; Anita Feleus; Martine A Hesselink; Jean W Muris; Reinhold W Stockbrügger; Maurice G Russel
Journal:  Inflamm Bowel Dis       Date:  2002-11       Impact factor: 5.325

2.  Inflammatory bowel disease: epidemiology and management in an English general practice population.

Authors:  G P Rubin; A P Hungin; P J Kelly; J Ling
Journal:  Aliment Pharmacol Ther       Date:  2000-12       Impact factor: 8.171

3.  Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.

Authors:  A Robinson; D G Thompson; D Wilkin; C Roberts
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

4.  Inflammatory bowel disease: costs-of-illness.

Authors:  J W Hay; A R Hay
Journal:  J Clin Gastroenterol       Date:  1992-06       Impact factor: 3.062

5.  Inflammatory bowel disease: medical cost algorithms.

Authors:  A R Hay; J W Hay
Journal:  J Clin Gastroenterol       Date:  1992-06       Impact factor: 3.062

Review 6.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey.

Authors:  Teresa Longobardi; Philip Jacobs; Lieling Wu; Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

8.  A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease.

Authors:  A Kennedy; E Nelson; D Reeves; G Richardson; C Roberts; A Robinson; A Rogers; M Sculpher; D Thompson
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

9.  Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England.

Authors:  Margaret A Stone; John F Mayberry; Richard Baker
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-12       Impact factor: 2.566

10.  Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey.

Authors:  Teresa Longobardi; Philip Jacobs; Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  82 in total

Review 1.  Elderly patients and inflammatory bowel disease.

Authors:  Danielle Nimmons; Jimmy K Limdi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 2.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 3.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Costs of inflammatory bowel disease in Germany.

Authors:  Renee Stark; Hans-Helmut König; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 7.  Retrospective economic and outcomes analyses using non-US databases: a review.

Authors:  Lizheng Shi; Eric Q Wu; Meredith Hodges; Andrew Yu; Howard Birnbaum
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 8.  Hematopoietic cell transplantation for Crohn's disease; is it time?

Authors:  Y Leung; M Geddes; J Storek; R Panaccione; P L Beck
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

9.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

10.  Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota.

Authors:  Stefan D Holubar; Kirsten Hall Long; Edward V Loftus; Bruce G Wolff; John H Pemberton; Robert R Cima
Journal:  Dis Colon Rectum       Date:  2009-11       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.